We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.15B
AUM Growth
-$403M
Cap. Flow
-$229M
Cap. Flow %
-3.73%
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
64
Reduced
62
Closed
12

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$35.2M
2
SYK icon
Stryker
SYK
+$32.7M
3
UNH icon
UnitedHealth
UNH
+$27.9M
4
PODD icon
Insulet
PODD
+$25.5M
5
RMD icon
ResMed
RMD
+$25.5M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$56.7M
2
ARGX icon
argenx
ARGX
+$45.6M
3
INSM icon
Insmed
INSM
+$43.4M
4
BSX icon
Boston Scientific
BSX
+$42.4M
5
HUM icon
Humana
HUM
+$36.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Industrials 0.05%
3 Communication Services 0.02%
4 Technology 0.02%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$394M 6.4%
8,260,434
-39,080
-0.5% -$1.6M
ARGX icon
2
argenx
ARGX
$53.8B
$298M 4.83%
691,874
-119,142
-15% -$45.6M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$123B
$278M 4.52%
593,461
-75,289
-11% -$32.7M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$261M 4.25%
1,898,640
-157,234
-8% -$21.6M
ISRG icon
5
Intuitive Surgical
ISRG
$122B
$240M 3.9%
539,904
-142,282
-21% -$56.7M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$35.7B
$224M 3.63%
919,834
+1,550
+0.2% +$245K
BSX icon
7
Boston Scientific
BSX
$65.4B
$198M 3.22%
2,569,588
-579,088
-18% -$42.4M
RVMD icon
8
Revolution Medicines
RVMD
$39.6B
$195M 3.17%
5,029,100
-44,500
-0.9% -$1.66M
SYK icon
9
Stryker
SYK
$123B
$186M 3.02%
545,934
+96,594
+21% +$32.7M
MRNA icon
10
Moderna
MRNA
$24.5B
$186M 3.02%
1,563,735
-147,354
-9% -$18.6M
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$169M 2.75%
2,471,285
-348,197
-12% -$24.1M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$2.36B
$167M 2.72%
3,879,548
-126,452
-3% -$4.56M
ABT icon
13
Abbott
ABT
$175B
$167M 2.71%
1,606,153
+171,970
+12% +$18.2M
DXCM icon
14
DexCom
DXCM
$29.6B
$144M 2.34%
1,268,687
+47,490
+4% +$6M
INCY icon
15
Incyte
INCY
$23.4B
$131M 2.12%
2,153,504
+116
+0% +$6.57K
EW icon
16
Edwards Lifesciences
EW
$49.4B
$116M 1.89%
1,260,461
+157,325
+14% +$13.9M
CLDX icon
17
Celldex Therapeutics
CLDX
$2.77B
$110M 1.79%
2,971,615
+175,000
+6% +$6.6M
UNH icon
18
UnitedHealth
UNH
$387B
$105M 1.7%
205,675
+56,956
+38% +$27.9M
PODD icon
19
Insulet
PODD
$11.4B
$87.9M 1.43%
435,420
+141,592
+48% +$25.5M
BDX icon
20
Becton Dickinson
BDX
$43.6B
$81.2M 1.32%
347,333
-68,367
-16% -$16.1M
MDT icon
21
Medtronic
MDT
$106B
$78.8M 1.28%
1,001,747
-5,253
-0.5% -$431K
BHVN icon
22
Biohaven
BHVN
$2.32B
$70.8M 1.15%
2,040,853
+890,853
+77% +$35.2M
INSM icon
23
Insmed
INSM
$23.5B
$68.5M 1.11%
1,021,700
-1,120,143
-52% -$43.4M
ARVN icon
24
Arvinas
ARVN
$517M
$63.6M 1.03%
2,390,800
– –
TNDM icon
25
Tandem Diabetes Care
TNDM
$1.17B
$62.2M 1.01%
1,543,267
-488,621
-24% -$20.4M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2024 Portfolio in Review

As of Q2 2024, Bellevue Group held 178 positions worth $6.15B, down 6.1% from $6.56B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $229M in Q2 2024, closing 12 positions and reducing 62 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $34.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Edgewise Therapeutics worth $25.7M.

  • Bellevue Group's largest Q2 2024 buy was Edgewise Therapeutics: 1,428,929 shares worth $25.7M.
  • Bellevue Group added most to Biohaven in Q2 2024, an estimated $35.2M increase.
  • Bellevue Group's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $56.7M.
  • Bellevue Group fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $34.4M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.15B portfolio in Q2 2024.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2024.
  • Bellevue Group's portfolio value fell 6.1% quarter-over-quarter to $6.15B.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.